{
    "clinical_study": {
        "@rank": "137899", 
        "arm_group": [
            {
                "arm_group_label": "TD-8954", 
                "arm_group_type": "Experimental", 
                "description": "TD-8954 single infusion for 1 hour and 4 injections of saline every 6 hours"
            }, 
            {
                "arm_group_label": "Metoclopramide", 
                "arm_group_type": "Active Comparator", 
                "description": "Metoclopramide 4 doses every 6 hours for 24 hours and 1 hour infusion of saline"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is being conducted to evaluate the safety, tolerability and early efficacy of IV\n      TD 8954 compared to metoclopramide in critically ill subjects, aged 18 to 85 years, who are\n      admitted to the intensive care  require mechanical ventilation, and are intolerant to\n      enteral feeding."
        }, 
        "brief_title": "A Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of a Single Dose of Intravenous TD-8954 Compared With Metoclopramide in Critically Ill Patients With Enteral Feeding Intolerance", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Enteral Feeding Intolerance", 
        "condition_browse": {
            "mesh_term": "Critical Illness"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Intubated, on mechanical ventilation, and anticipated to remain on mechanical\n             ventilation for 2 days after enrollment into the study\n\n          -  Receiving enteral feeding and assessed to have developed EFI, as defined by a GRV\n             measurement \u2265250 mL within the 24 hours before randomization\n\n        Exclusion Criteria:\n\n          -  History of diabetic or idiopathic gastroparesis\n\n          -  Screening blood glucose >15 mmol/L (270 mg/dL) while receiving insulin\n\n          -  Impaired renal function, as defined by estimated glomerular filtration rate (eGFR)\n             <30 mL/min, as determined by the Cockcraft-Gault formula -Bilirubin concentration in\n             blood >2 times the upper limit of normal\n\n          -  ALT or AST >3 times upper limit of normal\n\n          -  Alkaline phosphatase >2 times upper limit of normal\n\n          -  Contraindication to enteral feeding\n\n          -  Opioid or other drug overdose as the primary reason for admission to Intensive Care\n             Unit (ICU)\n\n          -  Receipt of a drug that can be used as a gastric prokinetic agent\n\n          -  Receipt of agents known to directly influence the 5 HT4/acetylcholine prokinetic\n             mechanism"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01953081", 
            "org_study_id": "0082"
        }, 
        "intervention": [
            {
                "arm_group_label": "TD-8954", 
                "intervention_name": "TD-8954", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Metoclopramide", 
                "intervention_name": "Metoclopramide", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Metoclopramide"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Enteral feeding", 
        "lastchanged_date": "January 31, 2014", 
        "location": {
            "contact": {
                "email": "Stephanie.O'Connor@health.sa.gov.au", 
                "last_name": "Stephanie O'Connor", 
                "phone": "+61 (0)8 8222 4624"
            }, 
            "facility": {
                "address": {
                    "city": "Adelaide", 
                    "country": "Australia", 
                    "state": "South Australia", 
                    "zip": "TBD"
                }, 
                "name": "Royal Adelaide Hospital"
            }, 
            "investigator": {
                "last_name": "Marianne Chapman, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Australia"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of a Single Dose of Intravenous TD-8954 Compared With Metoclopramide in Critically Ill Patients With Enteral Feeding Intolerance", 
        "overall_contact": {
            "email": "Mmcgovern@theravance.com", 
            "last_name": "Mark McGovern", 
            "phone": "650-808-6400"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "AEs", 
            "measure": "To evaluate the safety and tolerability of a single IV dose of TD-8954 in subjects with enteral feeding intolerance (EFI)by measuring AEs and ability to tolerate feeding.", 
            "safety_issue": "Yes", 
            "time_frame": "6 Days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01953081"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "To evaluate the pharmacokinetics (PK) of IV TD-8954 with lab values of Tmax.", 
                "safety_issue": "No", 
                "time_frame": "6 Days"
            }, 
            {
                "measure": "To evaluate the pharmacodynamics (PD) of IV TD-8954 in subjects with EFI based on gastric emptying as measured by scintigraphy.", 
                "safety_issue": "No", 
                "time_frame": "1 day"
            }, 
            {
                "measure": "To evaluate the pharmacokinetics (PK) of IV TD-8954 with lab values of AUC.", 
                "safety_issue": "No", 
                "time_frame": "6 Days"
            }, 
            {
                "measure": "To evaluate the pharmacokinetics (PK) of IV TD-8954 with lab values of Cmax.", 
                "safety_issue": "No", 
                "time_frame": "6 Days"
            }, 
            {
                "measure": "To evaluate the pharmacokinetics (PK) of IV TD-8954 with breath tests", 
                "safety_issue": "No", 
                "time_frame": "6 Days"
            }
        ], 
        "source": "Theravance, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Theravance, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}